Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - C-Bridge Capital Forms AffaMed Therapeutics to Accelerate Commercialization of Biologics in China - February 15, 2019

Pharmacy News Article

 2/11/19 - C-Bridge Capital Forms AffaMed Therapeutics to Accelerate Commercialization of Biologics in China

SHANGHAI, China, Feb. 11, 2019 (GLOBE NEWSWIRE) AffaMed Therapeutics, a new biopharmaceutical company founded and funded by C-Bridge Capital, a healthcare private equity firm focused on the development and late-stage investment opportunities, announced today that it is partnering with Samsung Bioepis to accelerate the commercialization of multiple next-generation biosimilars in China. Pharmaceutical industry veteran, Dr. Nathan Pang, will lead the Company as CEO.

AffaMed Logo

The licensed products include SB3 referencing trastuzumab (Herceptin), which received approval from the U.S. Food & Drug Administration (FDA) and European Medicines Agency for sale in the European Union, SB11 referencing ranibizumab (Lucentis), which is currently undergoing Phase 3 trials in the U.S and SB12 referencing eculizumab (Soliris).

Dr. Pang's deep industry knowledge and extensive leadership skills will be invaluable as the company develops and expands its portfolio of products, said Dr. Michael Keyoung, M.D., Ph.D., Chair of the Board of Directors at AffaMed and Managing Director at C-Bridge Capital. His previous leadership roles coupled with his expertise of the biopharmaceutical industry make him well suited to lead AffaMed.

Dr. Pang has more than 20 years of experience as a physician and a healthcare executive. Prior to joining AffaMed Therapeutics, he was the General Manager of Sanofi Pasteur China, where he expanded the company's pipeline by securing licensing agreements with Janssen China and Merck (MSD) China. Before that, he was the CEO of Sandoz China, the Generics Division of Novartis Group, during which he started up and grew the business to an organization with commercialised portfolio and profitable revenue. Previously, he was the Asia Pacific Regional Head for the Novartis Oncology Business Unit overseeing 14 countries in Asia including China. Dr. Pang holds a Bachelor of Medicine; Bachelor of Surgery (M.B.B.S) from the National University of Singapore and Bachelor of Law from the University of London, as well as a dual EMBA from France's INSEAD and China's Tsinghua University.

We are thrilled to partner with Samsung Bioepis, a proven leader in the global biosimilar industry, to develop these next-generation biologic candidates for patients in China, Dr. Pang said. Our team's clinical, regulatory and commercial experience with innovative biologics makes AffaMed uniquely suited to advance the development and registration of these products in China.

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on identifying and licensing late-stage candidates for commercialization in emerging Asia Pacific markets and globally. AffaMed was founded and funded by C-Bridge Capital in 2019.

About C-Bridge Capital

C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late-stage investment opportunities across the healthcare industry. C-Bridge Capital is committed to supporting the commercialization of cutting-edge technologies and companies that fulfil unmet medical needs, thus continuously improving the standard and quality of care for patients.


Media in US and Europe:
James Heins
Senior Vice President
Westwicke PR, an ICR Company
Tel. +1 203-682-8251

Media in Asia:
Edmond Lococo
Senior Vice Present
ICR Asia
+86(10) 6583-7510


Source: C-Bridge Capital

2019 GlobeNewswire, Inc.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement